18F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: A validation study

Journal of Nuclear Medicine

Volumn 47, Issue 6, 2006, Pages 1016-1022

  Iozzo, Patricia ^a,b   Gastaldelli, Amalia ^b   Järvisalo, Mikko J ^a   Kiss, Jan ^a   Borra, Ronald ^a   Buzzigoli, Emma ^b   Viljanen, Antti ^a   Naum, G ^a   Viljanen, Tapio ^a   Oikonen, Vesa ^a   Knuuti, Juhani ^a   Savunen, Timo ^a   Salvadori, Piero A ^b   Ferrannini, Ele ^b,c   Nuutila, Pirjo ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

6,6 2H glucose; 18F FDG; Glucose production; Glucose turnover; Insulin

Indexed keywords

6,6 GLUCOSE H 2; FLUORODEOXYGLUCOSE F 18; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; GLUCOSE; INSULIN; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; GLUCONEOGENESIS; HYPERINSULINEMIA; METABOLIC CLEARANCE RATE; NONHUMAN; PRIORITY JOURNAL; SWINE; VALIDATION STUDY; ANIMAL; BLOOD; COMPUTER ASSISTED DIAGNOSIS; DRUG EFFECT; EVALUATION; METABOLISM; METHODOLOGY;

ANIMALS; FASTING; FLUORODEOXYGLUCOSE F18; GLUCOSE; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INSULIN; METABOLIC CLEARANCE RATE; RADIOPHARMACEUTICALS; SWINE;

EID: 33746053886     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Williams KV, Bertoldo A, Mattioni B, Price JC, Cobelli C, Kelley DE. Glucose transport and phosphorylation in skeletal muscle in obesity: insight from a muscle-specific positron emission tomography model. J Clin Endocrinol Metab. 2003;88:1271-1279.
2. Virtanen KA, Lonnroth P, Parkkola R, et al. Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. J Clin Endocrinol Metab. 2002;87:3902-3910.
3. Iozzo P, Hallsten K, Oikonen V, et al. Insulin-mediated hepatic glucose uptake is impaired in type 2 diabetes: evidence for a relationship with glycemic control. J Clin Endocrinol Metab. 2003;88:2055-2060.
4. Basu R, Chandramouli V, Dicke B, Landau B, Rizza R. Obesity and type 2 diabetes impair insulin-induced suppression of glycogenosis as well as gluconeogenesis. Diabetes. 2005;54:1942-1948.
5. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 1992;15:318-368.
6. Staehr P, Hother-Nielsen O, Levin K, Holst JJ, Beck-Nielsen H. Assessment of hepatic insulin action in obese type 2 diabetic patients. Diabetes. 2001;50:1363-1370.
7. Choi Y, Hawkins RA, Huang SC, et al. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver. J Nucl Med. 1994;35:818-823.
8. Munk OL, Bass L, Roelsgaard K, Bender D, Hansen SB, Keiding S. Liver kinetics of glucose analogs measured in pigs by PET: importance of dual-input blood sampling. J Nucl Med. 2001;42:795-801.
9. 18F-FDG PET study. J Nucl Med. 2003;44:682-689.
10. Cersosimo E, Judd RL, Miles JM. Insulin regulation of renal glucose metabolism in conscious dogs. J Clin Invest. 1994;93:2584-2589.
11. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
12. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
13. Wolfe RR. Radioactive and Stable Isotopes in Biomedicine. New York, NY: Wiley-Liss; 1992.
14. James DE, Burleigh KM, Kraegen EW. In vivo glucose metabolism in individual tissues of the rat: interaction between epinephrine and insulin. J Biol Chem. 1986;261:6366-6374.
15. Jenkins AB, Storlien LH, Chisholm DJ, Kraegen EW. Effects of nonesterified fatty acid availability on tissue-specific glucose utilization in rats in vivo. J Clin Invest. 1988;82:293-299.
16. Hays MT, Segall GM. A mathematical model for the distribution of fluorodeoxyglucose in humans. J Nucl Med. 1999;40:1358-1366.
17. Ferrannini E, Smith JD, Cobelli C, Toffolo G, Pilo A, DeFronzo RA. Effect of insulin on the distribution and disposition of glucose in man. J Clin Invest. 1985;76:357-364.
18. Bland JM, Altman DG. Statistical method for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-310.
19. Sindelar DK, Igawa K, Chu CA, Balcom JH, Neal DW, Cherrington AD. Effect of a selective rise in hepatic artery insulin on hepatic glucose production in the conscious dog. Am J Physiol. 1999;276:E806-E813.
20. Lang V, Vaugelade P, Bernard F, et al. Euglycemic hyperinsulinemic clamp to assess posthepatic glucose appearance after carbohydrate loading. I. Validation in pigs. Am J Clin Nutr. 1999;69:1174-1182.
21. Kraegen EW, James DE, Jenkins AB, Chisholm DJ. Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol. 1985;248: E353-E362.
22. 18F]fluorodeoxyglucose in skeletal muscles of obese and nonobese humans. Am J Physiol Endocrinol Metab. 2000;279:E1122-E1130.
23. 18F] fluorodeoxyglucose in human skeletal muscle. J Nucl Med. 1999;40:1798-1804.
24. 18F]FDG) and PET in combination with microdialysis. Diabetologia. 2001;44:2171-2179.
25. Hallsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes. 2002;51:3479-3485.
26. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991;73:1294-1301.
27. Paolisso G, Tagliamonte MR, Rizzo MR, et al. Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. Am J Cardiol. 1999;83:1338-1344.
28. Fath-Ordoubadi F, Pagano D, Marinho NV, Keogh BE, Bonser RS, Camici PG. Coronary revascularization in the treatment of moderate and severe postischemic left ventricular dysfunction. Am J Cardiol. 1998;82:26-31.
29. Tayek JA, Manglik S, Abemayor E. Insulin secretion, glucose production, and insulin sensitivity in underweight and normal-weight volunteers, and in underweight and normal-weight cancer patients: a Clinical Research Center study. Metabolism. 1997;46:140-145.
30. Tayek JA. A review of cancer and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr. 1992;11:445-456.
31. Koea JB, Shaw JH. The effect of tumor bulk on the metabolic responses to cancer. Ann Surg. 1992;215:282-288.
32. Jee SH, Kim HJ, Lee J. Obesity, insulin resistance and cancer risk. Yonsei Med J. 2005;46:449-455.
33. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005;294:2872-2878.
34. Tayek JA, Sutter L, Manglik S, Lillington LB, Grosvenor M, Chlebowski RT. Altered metabolism and mortality in patients with colon cancer receiving chemotherapy. Am J Med Sci. 1995;310:48-55.
35. Berstein LM, Kvatchevskaya JO, Poroshina TE, et al. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol. 2004;130:687-693.
36. Tayek JA, Chlebowski RT. Metabolic responses to chemotherapy in colon cancer patients. J Parenter Enteral Nutr. 1992:16(suppl 6):65S-71S.
37. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54:862-871.